Machine Learning in Amyloidogenic Polypeptide Research: From Sequence Prediction to Drug Discovery
6 affiliations
- 1Anyang Institute of Technology , , ,
- 2Henan Provincial Key Laboratory of Intelligent Rehabilitation Equipment , ,
- 3West China Tianfu Hospital, Sichuan University , , ,
- 4The First People’s Hospital of Shihezi City , ,
- 5Sichuan University , , ,
- 6West China Hospital , , ,
Abstract
Over the past decade, machine learning (ML) has established a transformative paradigm for investigating amyloidogenic polypeptides. Characterized by their propensity to form ordered, β-sheet-rich fibrillar aggregates, these polypeptides are centrally implicated in the pathogenesis of numerous neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD). This review systematically evaluates the application of ML across critical domains of amyloid investigation: sequence-based amyloidogenicity prediction, structural biology, inhibitor design, and amyloid-related clinical objectives. We further summarize the diverse array of ML architectures currently employed in amyloid research, spanning classical algorithms (e.g., support vector machines and random forests) to advanced deep learning frameworks, such as the transformer framework, protein language models (PLMs), etc. Additionally, we spotlight emerging frontiers, namely, the integration of ML with molecular dynamics (MD) simulations, the use of generative AI for de novo inhibitor design, etc., while addressing persistent bottlenecks in the field, including data standardization, model interpretability, and rigorous experimental validation for in silico predictions. Ultimately, this review serves as a foundational roadmap for emerging researchers and a definitive reference for established investigators operating at the intersection of artificial intelligence and amyloid biology.
Related
- Machine Learning in Dementia Research: Trends, Biomarkers, Prediction Goals, and Data Modalities
- Enhanced cognitive protection through the combination of Amylovis-201, an anti-amyloidogenic agent with sigma-1 receptor agonist activity, and environmental enrichment in mice
- InRegPep: a web server for modeling of parallel beta-sheet fibrillar aggregates of amyloidogenic peptides
- From Discovery to Verification: A Thirty-Three-Year Analysis of Research Design in Three Leading General Medical Journals, 1992–2024
- From biomarker discovery to prediction models: clinical translation of multi-omics for early prediction of gestational diabetes mellitus
BibTeX
@article{zhang2026machine,
title = {{Machine Learning in Amyloidogenic Polypeptide Research: From Sequence Prediction to Drug Discovery}},
author = {Guocheng Zhang and Hairui Li and Xudong Zhen and Yang Liu and Libin Huang},
journal = {ACS Omega},
year = {2026},
month = oct,
doi = {10.1021/acsomega.6c06653},
url = {https://pubs.acs.org/acsodf/article/11/41/62296/5448170/Machine-Learning-in-Amyloidogenic-Polypeptide},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Machine Learning in Amyloidogenic Polypeptide Research: From Sequence Prediction to Drug Discovery
AU - Guocheng Zhang
AU - Hairui Li
AU - Xudong Zhen
AU - Yang Liu
AU - Libin Huang
PY - 2026
DA - 2026/10/09
JO - ACS Omega
DO - 10.1021/acsomega.6c06653
UR - https://pubs.acs.org/acsodf/article/11/41/62296/5448170/Machine-Learning-in-Amyloidogenic-Polypeptide
AB - Over the past decade, machine learning (ML) has established a transformative paradigm for investigating amyloidogenic polypeptides. Characterized by their propensity to form ordered, β-sheet-rich fibrillar aggregates, these polypeptides are centrally implicated in the pathogenesis of numerous neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD). This review systematically evaluates the application of ML across critical domains of amyloid investigation: sequence-based amyloidogenicity prediction, structural biology, inhibitor design, and amyloid-related clinical objectives. We further summarize the diverse array of ML architectures currently employed in amyloid research, spanning classical algorithms (e.g., support vector machines and random forests) to advanced deep learning frameworks, such as the transformer framework, protein language models (PLMs), etc. Additionally, we spotlight emerging frontiers, namely, the integration of ML with molecular dynamics (MD) simulations, the use of generative AI for de novo inhibitor design, etc., while addressing persistent bottlenecks in the field, including data standardization, model interpretability, and rigorous experimental validation for in silico predictions. Ultimately, this review serves as a foundational roadmap for emerging researchers and a definitive reference for established investigators operating at the intersection of artificial intelligence and amyloid biology.
SN - 2470-1343
ER -